SGLT2: new approaches to combination therapy of type 2 diabetes mellitus
https://doi.org/10.21518/2079-701X-2016-3-10-17
Abstract
Despite the emergence of new antidiabetic drugs, diabetes type 2 treatment remains a relevant issue. In order to standardize and optimize medical care to patients with diabetes, global and national algorithms for type 2 diabetes treatment were developed. [1, 2] The current algorithms focus on an individual approach, safety and effectiveness of treatment. A balance should be maintained between achieving optimal glycemic control and safety of therapy.
About the Authors
I. V. Kononenko
Endocrinological Scientific Centre
Russian Federation
Russian Federation
O. M. Smirnova
Endocrinological Scientific Centre
Russian Federation
Russian Federation
References
1. Inzucchi SE, BergenstaL RM, Buse JB, Diamant M et aL. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015, 38, 1: 140-149.
2. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой. М., 2015. Вып. 7.
3. Michael D Feher, Ma'en AL-Mrayat. ToLerabiLity of ProLonged-ReLease Metformin (GLucophage) in individuals intoLerant to standard metformin-resuLts from four UK centres. British J Diabetes and Vascular Diseade, 2007, 7(5): 225-228.
4. Turner RC et aL. GLycemic controL with diet, suL-fonyLurea, metformin, or insuLin in patients with type 2 diabetes meLLitus. Progression requirement for muLtipLe therapies (UKPDS 49). Jama, 1999, June 2, 281, 21: 2005-2012.
5. DeFronzo RA, Davidson JA, DeL Prato S. The roLe of the kidneys in gLucose homeostasis: a new path towards normaLizing gLycaemia. Diabetes Obes. Metab., 2012, 14(1): 5-14.
6. Мкртумян А.М., Егшатян Л.В. Новый неинсулинзависимый подход к терапии сахарного диабета 2 типа. Дапаглифлозин: результаты клинических исследований. Эффективная фармакотерапия, 2015, 11: 17-24.
7. Forxiga.EMA.http//www.ema.europa.eu/ema/ index.jsp?curL=pages/medicines/human/ mеdicines/002322/human_med_001546. jsp&mid.
8. FDA approves Farxiga to treat type 2 diabetes. U.S. Food and Drug Administration. http://www. fda.gov/newsevents/newsroom/pressannounce-ments/ucm380829.htm.
9. BoLinder J et aL. DapagLifLozin maintains gLy-caemic controL whiLe reducing weight andbody fat mass over 2 years in patients with type 2 diabetes meLLitus inadequateLy controLLed on metformin. Diabetes Obes Metab, 2014, 16: 15969. doi: 10.1111/dom.12189/.
10. Инструкция по медицинскому применению лекарственного препарата Форсига® (таблетки, покрытые пленочной оболочкой, 5 мг). Регистрационное удостоверение ЛП-002596 от 21/08/2014.
11. Henry RR, Murray AV, MarmoLejo MH et aL. DapagLifLozin, metformin-XR, or both: initial pharmacotherapy for type 2 diabetes, a randomized controLLed triaL. Int. J. Clin. Pract., 2012, 66: 446-456.
12. Ferrannini E, Ramos SJ, SaLsaLi A, Tang W, List JF. DapagLifLozin monotherapy in type 2 diabetic patients with inadequate gLycemic controL by diet and exercise: a randomized, doubLe-bLind, pLacebo-controLLed, phase 3 triaL. Diabetes Care, 2010, 33(10): 2217-24.
13. BaiLey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagLifLozin in patients with type 2 diabetes who have inadequate gLycaemic controL with metformin: a randomised, doubLe-bLind, pLacebo-controLLed triaL. Lancet, 2010, 375(9733): 2223-33.
14. BaiLey CJ, Gross JL, Hennicken D, IqbaL N, MansfieLd TA, List J. DapagLifLozin add-on to metformin in type 2 diabetes inadequateLy controLLed with metformin: a randomized, doubLe-bLind, pLacebo-controLLed 102-week triaL. BMCMedicine, 2013, 11: 43.
15. Henry RR, Murray AV, MarmoLejo MH, Hennicken D, Ptaszynska A, List JF. DapagLifL ozin, metformin XR, or both: initiaL pharmacotherapy for type 2 diabetes, a randomised controLLed triaL. Int. J. Clin. Pract., 2012, 66(5): 446-56.
16. Nauck MA, DeL Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, ELze M, Parikh SJ. DapagLifLozin versus gLipizide as add-on therapy in patients with type 2 diabetes who have inadequate gLycemic controL with metformin: a randomized, 52-week, doubLe-bLind, active-controLLed non-inferiority triaL. Diabetes Care, 2011, 34(9): 2015-22.
17. Nauck MA, DeL Prato S, Duran-Garcia S, Rohwedder K, LangkiLde AM, Sugg J, Parikh SJ. DurabiLity of gLycaemic efficacy over 2 years with dapagLifLozin versus gLipizide as add-on therapies in patients whose type 2 diabetes meLLitus is inadequateLy controLLed with met-formin. Diabetes Obes. Metab., 2014, 16(11): 1111-20.
18. DeL Prato S, Nauck M, Duran-Garcia S, Maffei L, Rohwedder K, Theuerkauf A, Parikh S. Long-term gLycaemic response and toLerabiLity of dapagLifLozin versus a suLphonyLurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab, 2015 Jun, 17(6): 581-90. doi: 10.1111/ dom.12459. Epub 2015 Apr 6.
19. Serge A. Jabbour, ELise Hardy, Jennifer Sugg, Shamik Parikh. DapagLifLozin Is Effective as Add-on Therapy to SitagLiptin With or Without Metformin: A 24-Week, MuLticenter, Randomized, DoubLe-BLind, PLacebo-ControLLed Study. Diabetes Care, 2014, 37: 740-50.
20. Mathieu C et aL. Diabetes Care, 2015 Aug 5.
21. Zachary T. BLoomgarden and Yehuda HandeLsman. SGLT-2 inhibition added to GLP-1 agonist therapy for type 2 diabetes: What is the benefit? Endocrine Practice, 2015 December, 21, 12: 1442-1444.
22. Strojek K, Yoon KH, Hruba V, ELze M, LangkiLde AM, Parikh S. Effect of dapagLifLozin in patients with type 2 diabetes who have inadequate gLycaemic controL with gLimepiride: a randomized, 24-week, doubLe-bLind, pLacebo-controLLed triaL. Diabetes Obes Metab., 2011 Oct, 13(10): 928-38. doi: 10.1111/j.1463-1326.2011.01434.x.
23. Hemmingsen B, Christensen LL, WettersLev J et aL. Comparison of metformin and insuLin versus insuLin aLone for type 2 diabetes: systematic review of randomised cLinicaL triaLs with meta-anaLyses and triaL sequentiaL anaLyses. BMJ, 2012: 344.
24. WiLding JPH, Woo V, Rohwedder K, Sugg J & Parikh S for the DapagLifLozin 006 Study Group. DapagLifLozin in patients with type 2 diabetes receiving high doses of insuLin: efficacy and safety over 2 years. Diabetes, Obesity and Metabolism, 2014, 16: 124-136.
25. BenfieLd T, Jensen JS, Nordestgaard BG. InfLuence of diabetes and hypergLycaemia on infectious disease hospitaLization and outcome. Diabetologia, 2007, 50, 3: 549-554.
26. De Leon EM, Jacober SJ, SobeL JD, Foxman B. PrevaLence and risk factors for vaginaL Candida coLonization in women with type 1 and type 2 diabetes. BMC Infect. Dis., 2002, 2, 1.
27. GeerLings S, Fonseca V, Castro-Diaz D et aL. GenitaL and urinary tract infections in diabetes: impact of pharmacoLogicaLLy-induced gLucosuria. Diabetes Res. Clin. Pract., 2014, 103, 3: 373-381.
28. Johnsson KM, Ptaszynska A, Schmitz B et aL. Urinary tract infections in patients with diabetes treated with dapagLifLozin. J. Diabetes Complications, 2013, 27, 5: 473-478.
29. Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TWA et aL. Safety profiLe of dapagLifLozin for type 2 diabetes: PooLed AnaLysis of CLinicaL Studies for OveraLL Safety and Rare Events. Drug Saf., 2014, 37: 815-29.
30. Johnsson KM, Ptaszynska A, Schmitz B et aL. Vulvovaginitis and baLanitis in patients with diabetes treated with dapagLifLozin. J. Diabetes Complications, 2013, 27, 5: 479-484.
31. NicoLLe LE, Capuano G, Ways K, Usiskin K. Effect of canagLifLozin, a sodium gLucose co-transporter 2 (SGLT2)inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enroLLed in a 12-week, phase 2 study. Curr Med Res Opin, 2012, 28(7): 1167-71.
32. Nyirjesy P, Zhao Y, Ways K, Usiskin K. EvaLuation of vuLvovaginaL symptoms and Candida coLonization in women with type 2 diabetes meLLitus treated with canagLifLozin, a sodium gLucose co-transporter 2 inhibitor. Curr Med Res Opin, 2012, 28(7): 1173-8.
33. Ferrannini E, Seman L, SeewaLdt-Becker E, HanteL S, Pinnetti S, WoerLe HJ. A Phase lib, randomized, pLacebocontroLLed study of the SGLT2 inhibitor empagLifLozin in patients with type 2 diabetes. Diabetes Obes Metab, 2013.
34. Rosenstock J, Seman LJ, JeLaska A, HanteL S, Pinnetti S, Hach T, et aL. Efficacy and safety of empagLifLozin, a sodium gLucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with miLd hypergLycaemia. Diabetes Obes Metab, 2013, 15(12): 1154-60.
35. https://cLinicaLtriaLs.gov/ct2/show/study/ NCT01730534?term=DECLARE.
36. DeL Prato S, et aL. Diabetes Obes Metab. 2015 Jun, 17(6): 581-90.
37. Algorithms of specialized medical care to patients with diabetes. Edited by II Dedov, M.V. Shestakova. М., 2015. Vol. 7.
38. Mkrtumian A.M., Egshatyan L.V. A new non-insulin dependent approach to the treatment of type 2 diabetes. Dapagliflozin: results of clinical trials. Effektivnaya Farmakoterapiya, 2015, 11: 17-24
39. Instruction for medical use of Forxiga® 5 mg & 10 mg film coated tablets. Registration Certificate LP-002596 of 21.08.2014.
Review
For citations:
Kononenko IV, Smirnova OM. SGLT2: new approaches to combination therapy of type 2 diabetes mellitus. Meditsinskiy sovet = Medical Council. 2016;(3):10-17. (In Russ.) https://doi.org/10.21518/2079-701X-2016-3-10-17
Views:
857
Email this article 